PARDES BIOSCIENCES, INC.

FS Development Corp. II, listed under the ticker FSII, was a life sciences-focused special purpose acquisition company that completed its initial public offering in early 2021. Sponsored by FS Development Corp. II Sponsor LLC, the vehicle was formed to pursue a business combination with a company in the biopharmaceutical or broader healthcare sector. FSII subsequently entered into and completed a merger with Pardes Biosciences, Inc., a clinical-stage antiviral drug discovery company focused on developing oral therapeutics targeting COVID-19 and related coronaviruses. The February 2021 Form 8-K filing under accession 0001213900-21-011706 represents an early corporate disclosure tied to the SPAC's formation and IPO lifecycle. Sign up at SpacDesk for the full filing history, deal timeline, and analytics on FSII and the broader SPAC universe.